ACHIEVE LIFE SCIENCES, INC.

Vancouver, B.C., A1 · Biotech · Public

Cytisine, a partial nicotinic acetylcholine receptor agonist molecule for e-cigarette and smoking cessation

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · achievelifesciences.com

Sector: Biotech
Headquarters: Vancouver, B.C., A1
Latest Form D: $18.9M, Nov 2022
Total capital: $31.7M

Federal grants: $2.8M; 3 awards · 2021–2023; Rank in peer group#368 of 514
Private capital raised: $28.9M; 2 Form D · last Nov 2022; 47 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 3; 14 pending · first 2021; Rank in peer group#109 of 514

Capital timeline

Latest events

Jul 2023Federal grantHealth and Human S · Phase II · Benefit and Safety of Cytisinicline (cytisine) for Cessation of Nicotine E-cigarette Use$585K
Nov 2022Private capital raisedForm D · SEC · 2nd filing$18.9M
May 2022Federal grantHealth and Human S · Phase II · Benefit and Safety of Cytisinicline (cytisine) for Cessation of Nicotine E-cigarette Use$1.9M
Jul 2021Federal grantHealth and Human S · Phase II · Benefit and Safety of Cytisinicline (cytisine) for Cessation of Nicotine E-cigarette Use$320K
Jan 2010Private capital raisedForm D · SEC · 1st filing$10M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#109 · top 21%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Cindy JacobsResearcherExecutive Officer, DirectorLinked by 2 patents · $2.8M in grants as PI
Anthony ClarkeExecutive OfficerNamed in SEC Form D filings
Bridget MartellDirectorNamed in SEC Form D filings
Donald JosephDirectorNamed in SEC Form D filings
Jaime XinosExecutive OfficerNamed in SEC Form D filings
Jay MoyesDirectorNamed in SEC Form D filings

Show all 10 people

John BencichExecutive Officer, DirectorNamed in SEC Form D filings
Martin MattinglyDirectorNamed in SEC Form D filings
Richard StewartDirectorNamed in SEC Form D filings
Vaughn HimesDirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 17

Jun 11, 2026PendingCompositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofUSPTOApplication 19267375
Jun 11, 2026PendingCompositions For Treating And/or Preventing Substance Use Disorders In Subjects In Need ThereofUSPTOApplication 18977296
Sep 23, 2025GrantedAnalytical Methods Of Assessing Cytisine PurityUSPTOUS 12,422,415

Show all 17 patent records

Compositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofJun 11, 2026 · Application 19267375Pending
Compositions For Treating And/or Preventing Substance Use Disorders In Subjects In Need ThereofJun 11, 2026 · Application 18977296Pending
Analytical Methods Of Assessing Cytisine PuritySep 23, 2025 · US 12,422,415Granted
Smoking Cessation Compounds Having Reduced Nitrosamines And Associated MethodsJun 12, 2025 · Application 18977173Pending
Cytisine FormulationsJun 12, 2025 · Application 18977247Pending
Compositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofOct 28, 2021 · Application 17366497Pending
Compositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofAug 10, 2021 · US 11,083,715Granted
Compositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofAug 10, 2021 · US 11,083,716Granted
Smoking Cessation Compounds Having Reduced Nitrosamines And Associated MethodsApplication 63608935Pending
Cytisine FormulationsApplication 63608959Pending
Methods Of Control And Analysis Of N-nitrosocytisine In Cytisine SamplesApplication PCTUS2024033761Pending
Analytical Methods Of Assessing Cytisine PurityApplication PCTUS2022042699Pending
Analytical Methods Of Assessing Cytisine PurityApplication 63241829Pending
Cytisine FormulationsApplication PCTUS2024059604Pending
Smoking Cessation Compounds Having Reduced Nitrosamines And Associated MethodsApplication PCTUS2024059590Pending
Compositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofApplication PCTUS2020046308Pending
Compositions Comprising Cytisine In The Treatment And/or Prevention Of Addiction In Subjects In Need ThereofApplication PCTUS2024026187Pending

Inspira Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
SAVARA, INC.Similar federal contract value in Biotech · null in contracts
MARKER THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
CELLIBRE INCSimilar federal contract value in Biotech · null in contracts
ALIDA BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
RODIN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.